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Abstract 
Background: The biosynthesis pathway of benzoxazole compounds caboxamycin and nataxazole have been 
recently elucidated. Both compounds share one of their precursors, 3-hydroxyanthranilate (two units in the case 
of nataxazole). In addition, caboxamycin structure includes a salicylate moiety while 6-methylsalycilate is the third 
scaffold in nataxazole. Pathways cross-talk has been identified in caboxamycin producer Streptomyces sp. NTK937, 
between caboxamycin and enterobactin pathways, and nataxazole producer Streptomyces sp. Tü6176, between natax-
azole and coelibactin pathways. These events represent a natural form of combinatorial biosynthesis.
Results: Eleven novel caboxamycin derivatives, and five putative novel derivatives, bearing distinct substitutions in 
the aryl ring have been generated. These compounds were produced by heterologous expression of several caboxa-
mycin biosynthesis genes in Streptomyces albus J1074 (two compounds), by combinatorial biosynthesis in Strepto-
myces sp. NTK937 expressing nataxazole iterative polyketide synthase (two compounds) and by mutasynthesis using 
a nonproducing mutant of Streptomyces sp. NTK937 (12 compounds). Some of the compounds showed improved 
bioactive properties in comparison with caboxamycin.
Conclusions: In addition to the benzoxazoles naturally biosynthesized by the caboxamycin and nataxazole produc-
ers, a greater structural diversity can be generated by mutasynthesis and heterologous expression of benzoxazole 
biosynthesis genes, not only in the respective producer strains but also in non-benzoxazole producers such as S. albus 
strains. These results show that the production of a wide variety of benzoxazoles could be potentially achieved by the 
sole expression of cbxBCDE genes (or orthologs thereof ), supplying an external source of salicylate-like compounds, 
or with the concomitant expression of other genes capable of synthesizing salicylates, such as cbxA or natPK.
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Background
Sequencing of Streptomyces sp. NTK937 genome, a deep-
sea sediment strain, revealed up to 35 putative gene clus-
ters for the biosynthesis of secondary metabolites [1], 
including that for the biosynthesis of antibiotic caboxa-
mycin. This compound belongs to the family of benzoxa-
zoles [2], which includes compounds such as calcimycin 
[3], nataxazole [4], and A33853 [5], whose respective 
biosynthesis pathways have been characterized [6–9]. 
The benzoxazole scaffold is known to bear different phar-
macological properties such as being cytotoxic and/or 
antibiotic [10], possessing anti-leishmanial properties 
[11], or inhibiting the replication of hepatitis C virus [12].
Recently, our group has elucidated the pathway for 
caboxamycin biosynthesis comprising nine structural 
genes, cbxA-I (Fig. 1a). Caboxamycin derives from choris-
mate through the generation, activation and condensa-
tion of two precursors, 3-hydroxyanthranilate (3HAA) 
and salicylate (SA) [13]. Five of the estructural genes, 
cbxA, cbxB, cbxD and cbxE, encoding a salicylate syn-
thase, 3-oxoacyl-ACP-synthase, ACP, and amidohydrolase 
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respectively, were found essential for caboxamycin biosyn-
thesis. The remaining structural genes, cbxC, cbxF, cbxG, 
cbxH and cbxI, encoding a AMP-dependent synthetase-
ligase, 3-deoxy-d-arabinohept-2-ulosonate-7-phosphate 
synthase, 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase, isochorismatase and anthranilate synthase respec-
tively, have paralogs distributed throughout Streptomyces 
sp. NTK937 genome and thus they are not essential for the 
biosynthesis of caboxamycin. In addition, the biosynthesis 
gene cluster contains a positive SARP-like transcriptional 
regulator, cbxR. In this previous study, Streptomyces sp. 
NTK937 has been shown to naturally produce two dif-
ferent compounds: caboxamycin (1) and its methyl ester, 
O-methylcaboxamycin (2) (Fig.  1b), whose biosynthe-
sis depends on an uncharacterized O-methyltransferase 
located neither within nor near the cluster. Furthermore, 
upon gene replacement of the salicylate synthase cbxA, a 
third compound was observed, 3′-hydroxycaboxamycin 
(3) (Fig.  1b), stemming from the cross-talk between the 
caboxamycin biosynthesis pathway and 2,3-dihydroxyben-
zoate (DHB) generated in the biosynthetic pathway for the 
siderophore enterobactin [13]. This phenomenon, together 
with our previous studies of the nataxazole biosynthetic 
cluster, where we identified cross-talk between the nataxa-
zole and coelibactin biosynthesis pathways that led to bio-
synthesis of benzoxazole UK-1 [7, 8], sparked our interest 
for the generation of novel benzoxazoles exploring the bio-
combinatorial potential of these family of compounds.
In this work we report the generation of 16 novel 
caboxamycin derivatives (4–19) bearing distinct sub-
stitutions in the aryl ring have been generated. These 
compounds were produced by using different molecular 
approaches such as heterologous expression of selected 
genes, combinatorial biosynthesis using genes from dif-
ferent pathways and feeding different precursors to 
selected mutants by mutasynthesis.
Results
Heterologous expression of caboxamycin biosynthesis 
genes in Streptomyces albus J1074
The structural genes from the caboxamycin biosynthesis 
cluster, cbxABCDEFGHI, have previously been expressed 
as a whole in Streptomyces lividans JT46 as heterolo-
gous host, leading to the production of caboxamycin 
[13]. Since paralogs to cbxFGHI exist in Streptomyces 
sp. NTK937 (probably involved in primary metabolism) 
we assumed that a similar situation could occur in other 
Streptomyces spp. Subsequently we aimed to induce 
the heterologous production of caboxamycin by solely 
expressing the cbxABCDE genes, encoding a salicylate 
synthase, oxoacyl-ACP synthase, AMP-dependant syn-
thetase-ligase, ACP and amidohydrolase respectively, in 
two Streptomyces albus strains: S. albus J1074 [14] and 
B29 [15]. The former produces the glycosylated antibiotic 
family of paulomycins that involves the participation of 
genes plm15-18, orthologs to cbxFGHI and responsible 
for the biosynthesis of the 3HAA-derived core of paulo-
mycins [16]. On the other hand, in S. albus B29, genes 
plm15-16, orthologs of cbxHI, have been replaced by an 
apramycin resistance cassette, thus blocking paulomy-
cin biosynthesis [15]. Expression of cbxABCDE under 
the control of constitutive promoter ermE*p [17] using a 
pSET152-derived plasmid, pSET-cbxABCDE, afforded a 
substantial production of 1 in both strains (Fig. 2), clearly 
showing the existence of orthologs for cbxFGHI within 
primary metabolism genes in the host strains. In addi-
tion, two novel products were generated (Fig.  2): com-
pound 4, a benzoxazole-hydroxylated version of 1, barely 
detectable in the J1074 strain, but clearly produced in the 
B29 strain (Additional file 2: Table S1, Additional file 3: 
Figure S3); and 5, a p-aminobenzoate (PABA) amide-
linked to a salicylate moiety, present in both strains 
(Additional file 2: Table S2, Additional file 3: Figure S4).
Heterologous expression of natPK in Streptomyces sp. 
NTK937
Within the scope of our research, ortholog genes from 
the related biosynthetic cluster of benzoxazole nataxa-
zole [7] were heterologously expressed in several Strepto-
myces sp. NTK937 caboxamycin non-producing mutants, 
successfully restoring caboxamycin biosynthesis in all 
cases, except for the amidohydrolase coding natAM [13]. 
However, the nataxazole cluster also contains a struc-
tural gene with no ortholog in caboxamycin biosynthesis, 
natPK, an iterative type I polyketide synthase responsi-
ble for the biosynthesis of the 6-methylsalicylate (6MSA) 
moiety present in nataxazole. This gene was expressed, 
using plasmid pnatPK, in the Streptomyces sp. NTK937 
non-producing strain ΔcbxA, thus generating noticeable 
quantities of the precursor 6MSA (Fig. 3). Furthermore, 
Fig. 1 Caboxamycin biosynthesis gene cluster and chemical struc-
ture of related compounds. a Genetic organization of caboxamycin 
biosynthesis gene cluster. b Chemical structure of caboxamycin, 1; 
O-methylcaboxamycin, 2; and 3′-hydroxycaboxamycin, 3
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low levels of a caboxamycin derivative (6) were produced 
as a consequence of combinatorial biosynthesis. Com-
pound 6 carries both the aryl methylation characteristic 
of 6MSA, plus the methyl esterification ascribed to the 
unlocated O-methyltransferase (Additional file  2: Table 
S3, Additional file  3: Figure S5). We sought to improve 
production of 6 using plasmid constructs bearing both 
natPK and one of the AMP-dependant synthetase-ligases 
from the nataxazole cluster. The combined expression 
of natL1-natPK (pnatL1-PK) afforded the production of 
highest amounts of 6, whereas simultaneous expression 
of natL2-natPK (pnatL2-PK) favored instead the produc-
tion of 3.
A small peak observed in ΔcbxA/pnatL1-PK cultures, 
compound 7, with a retention time of 5.4  min (Fig.  3), 
possibly corresponds to the acid version of 6, given its 
coherently shorter than 6 (6.15  min) but higher than 1 
retention time (4.90  min). This peak was consistently 
observed along the different experiments performed, 
but its drastically low levels of production prevented its 
isolation and spectroscopic characterization, although 
HPLC–MS analysis is coherent with this hypothesis, 
showing a mass of m/z 270.07 [M+H]+.
Generation of novel derivatives by mutasynthesis
Upon observing how amenable Streptomyces sp. NTK937 
was to the combination of similar precursors to yield 
novel caboxamycins, we sought to obtain novel com-
pounds following a mutasynthesis approach, a strategy 
involving the addition of modified precursors in biosyn-
thetically-blocked mutants in order to afford novel deriv-
atives of the original product. As a host, the Streptomyces 
sp. NTK937 non-producing double mutant strain ΔcbxA/
ΔentC was selected, since syntheses of both SA and DHB 
are abolished, thus allowing for better resource allocation 
towards the production of novel caboxamycins.
A selection of different precursors, all bearing carbox-
ylate groups attached to cyclic molecules, was initially 
tested and it was found that under standard working 
conditions, the mutant strain only assimilates molecules 
of salicylate structure, i.e., aromatic acids with hydroxyl 
substitution in position 2, but allowing for extra substi-
tutions in other places. We selected an array of salicy-
lates bearing an additional individual substitution with 
a hydroxyl, methoxyl, methyl or chlorine group in all 
available positions, plus salicylates with an heteroatomic 
substitution with nitrogen in any position within the ring 
(pyridinic acids) (Additional file 1: Figure S1), and added 
them at 1 mM final concentration to the respective cul-
tures, resulting in the production of several novel com-
pounds, 8–19 (Figs.  4, 5) (Additional file  2: Figure S2, 
Tables S4–S11; Additional file 3: Figures S6–S13).
Fig. 2 Compounds generated by heterologous expression of 
caboxamycin biosynthesis genes in S. albus J1074. a UPLC analysis of 
Streptomyces sp. NTK937 wild-type and S. albus strains J1074 and B29 
harboring pSET-cbxABCDE or control plasmid pSETeTc. Chromato-
grams were analyzed at 330 nm. SA stands for salicylic acid. Asterisks 
indicate paulomycins and paulomenols. b Chemical structure of 
novel compounds 4 and 5
Fig. 3 Compounds generated by combinatorial biosynthesis in 
Streptomyces sp. NTK937. a UPLC analysis of Streptomyces sp. NTK937 
mutant strain ΔcbxA harboring plasmids pEM4T (control), pnatPK, 
pnatL1-PK or pnatL2-PK. Chromatograms were analyzed at 330 nm. 
6MSA stands for 6-methylsalicylic acid. b Chemical structure of novel 
compounds 6 and 7
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As expected, some of these compounds led to already 
characterized caboxamycins, such as the addition of SA 
behaving as a chemical complementation, restoring pro-
duction of 1 and 2; DHB yielding 3; or 6MSA resulting 
in 6 (but, again, barely a hint of the putative acid form 
7). On the other hand, some reagents spawned no ben-
zoxazoles in our culture conditions, such as 4-methox-
ysalicylate, which also seems to exert some hindering 
effect on the growth of this strain. Similarly, none of 
the pyridinic acids resulted in novel benzoxazoles, with 
the exception of 3-hydroxypicolinate (3HPA), a moi-
ety shared by related benzoxazole A33853 [9], with the 
remarkable difference that here it appears as compounds 
16 and 18, sporting a complete benzoxazole feature, as 
opposed to the open, amide-linked structure of A33853. 
Furthermore, compounds 17 and 19, which, like 5, are 
PABA-derived, were unexpectedly obtained by the incor-
poration of 3HPA, a feat not readily observed with any 
of the other salicylates used in these assays. Moreover, 
it is unknown whether the methylation on the carboxy-
late in 19 could be a consequence of the same esterifying 
enzyme responsible for the biosynthesis of 2.
Similarly to what occurs with compound 7, compounds 
11, 12, 13 and 15 (Fig. 5) represent peaks with distinctly 
benzoxazole-like absorption spectra (Additional file  2: 
Figure S2) and masses coherent with the expected prod-
ucts (m/z 270.08, 290.17, 290.15 and 304.08 [M+H]+, 
respectively), but these could not be adequately purified 
nor spectroscopically characterized due to low yields or 
presence of concomitant impurities, therefore remaining 
as putative novel caboxamycin derivatives and candidates 
for future experiments.
Biological activity
All novel caboxamycin derivatives characterized in this 
work were tested against a selection of microorganisms 
(Gram-negative Escherichia coli, Gram-positive Staphylo-
coccus aureus, Micrococcus luteus and S. albus, and yeast 
Candida albicans) via disk diffusion assay (Additional 
file  4: Table S12). Compounds 4, 8 and 9 were found to 
inhibit growth in all Gram-positive bacteria, with 9 show-
ing an additional mild inhibition of C. albicans growth. 
On the other hand, compound 14 was shown to selec-
tively inhibit the growth of S. aureus at 5 µg.
These compounds were likewise submitted to cytotox-
icity assays against tumor cell lines A549 (lung), MDA-
MB-231 (breast), HT29 (colon), AGS (gastric) and A2780 
(ovarian), using the murine fibroblast NIH/3T3 cell line 
as control (Additional file 4: Table S13). Most of the novel 
compounds show no activity under the selected cutoff 
level of 10  μM. However, compound 9 shows activity 
against all lines, which unfortunately includes the control 
cell line. On the other hand, compounds 4 and 8 could 
be of potential interest, as they seem to exert a selec-
tive cytotoxic effect against the gastric cell line AGS and 
ovarian cell line A2780 (compound 4), as well as a mild 
action against the lung cell line A549.
Discussion
The biosynthetic pathways of benzoxazole compounds 
nataxazole and caboxamycin show certain degree of flex-
ibility since natural events of cross-talk with other path-
ways lead to hybrid compounds. In the case of nataxazole 
Fig. 4 UPLC analysis of mutasynthesis assays in Streptomyces sp. 
NTK937 ΔcbxA/ΔentC. Chromatograms were analyzed at 330 nm. 
Asterisks indicate the precursor used. Sal. salicylate
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producer Streptomyces sp. Tü6176, the inactivation of 
polyketide synthase coding natPK led to the biosynthe-
sis of benzoxazole UK-1 where the 6-methylsalicylic acid 
moiety had been substituted by salicylic acid, produced 
by the coelibactin biosynthesis pathway. Production of 
UK-1 can be improved growing the mutant strain in a 
zinc-deficient medium [8]. On the other hand, inactiva-
tion of cbxA, encoding a salicylate synthase, in caboxa-
mycin producer Streptomyces sp. NTK937 led to the 
biosynthesis of 3′-hydroxycaboxamycin where the salicy-
late moiety had been substituted by 2,3-dihydroxybenzo-
ate, produced by the enterobactin biosynthesis pathway 
[13]. The biosynthesis of these compounds represents a 
natural form of combinatorial production that prompted 
us to attempt the generation of novel benzoxazoles using 
combinatorial biosynthesis, heterologus expression and 
mutasynthesis, approaches that have been successful in 
many other cases [18–21].
We have generated eleven novel caboxamycin deriva-
tives (compounds 4–6, 8–10, 12, 14 and 16–19), and 
five putative novel derivatives (compounds 7, 11–13 
and 15), (Fig. 6). The usual yield for wild-type cultures 
under same conditions is 1–2.5 mg for caboxamycin (1) 
and 0.2–0.7  mg for O-methylcaboxamycin (2). Com-
pounds 4 and 5 (14.3 and 6.8 mg, respectively), gener-
ated by heterologous expression in S. albus J1074, were 
obtained in greater amounts due to the ermE*p-enforced 
expression of the corresponding biosynthetic genes, and 
the lack of regulatory controls from its original strain. 
Compound 6, obtained by combinatorial biosynthesis 
in mutant strain ΔcbxA (0.2 mg), was produced at lev-
els coherent with those of wild-type strain Streptomy-
ces sp. NTK 937 for O-methylcaboxamycin (2). In the 
case of compounds 8–10, 14 and 16–19, these were iso-
lated with varying success but at levels similar to those 
of Streptomyces sp. NTK 937, with higher quantities for 
the acid form than for the corresponding methyl ester. 
We also sought to improve mutasynthesis yields by 
ectopic expression of regulatory gene cbxR in the strain 
ΔcbxA/ΔentC. However, production levels did not 
increase accordingly as in prior uses of cbxR [13], pos-
sibly due to the lack of cbxA, which might contain the 
effecting region for CbxR, given the structural organiza-
tion of the biosynthetic cluster.
Fig. 5 Chemical structure of compounds 8–19 obtained by mutasynthesis in Streptomyces sp. NTK937 ΔcbxA/ΔentC
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Some of these novel caboxamycin derivatives show 
improved antibiotic and cytotoxic activities (compounds 
4, 8 and 9). Especially remarkable is the fact that 4 can 
actually inhibit the growth of S. albus, the host strain 
where the compound was produced by combinatorial 
biosynthesis, a feat similar to that observed in the het-
erologous expression of the nataxazole cluster, whose 
unmethylated product, AJI9561, showed deleterious 
effects on the growth of the host strain [7]. On the other 
hand, the production of compound 4 in S. albus clearly 
shows the existence of orthologs for cbxFGHI within 
primary metabolism genes in S. albus strains, such as 
the biosynthetic pathway to aromatic amino acids [22, 
23], secondary metabolism pathways, such as the bio-
synthesis of catecholate siderophores [24], or even alter-
native routes leading to 3HAA via  NAD+ biosynthesis 
pathway from tryptophan catabolism [25]. In addition, 
hydroxylation of the 3HAA moiety of 4 might be medi-
ated by plm14 gene product, the immediate neigh-
bor of the replaced genes in S. albus strain B29, which 
encodes a 3-hydroxybenzoate 6-hydroxylase activity 
that participates in paulomycins biosynthesis [16]. Oth-
erwise, generation of 5 is serendipitous. It can only be 
surmised that stimulation of the chorismate pathway due 
to enforced salicylate biosynthesis by cbxA overexpres-
sion may activate other chorismate-derived routes such 
as PABA biosynthesis (Fig. 6), which naturally takes part 
as the first step towards folate biosynthesis [26]. Further-
more, PABA is a direct precursor of candicidins, polyene 
polyketides produced by S. albus J1074 [15]. No gene can 
be held responsible for the amide bond formation, since, 
to the best of our knowledge, no similar PABA-derived 
compounds of biological origin have been described 
in the literature, and non-ribosomal amide links can 
be achieved in several different ways [27]. On the other 
hand, the amide bond of compound 5 (Fig.  6) could be 
generated by CbxB that exerts a similar role during 
caboxamycin biosynthesis [13].
The production of some caboxamycin derivatives has 
also allowed confirming the roles previously assigned 
to some nataxazole biosynthesis genes [7]. That is the 
case for the generation of compound 6 by heterologous 
Fig. 6 Schematic representation of the biosynthetic origin of compounds 1–19
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expression of polyketide synthase coding natPK in Strep-
tomyces sp. NTK937, and the subsequent improvement 
of its yield by expressing AMP-dependant synthetase-
ligase coding natL1, while the coexpression of natPK and 
natL2 favored instead the production of 3. These results 
are in consonance with the assigned roles of NatL1 and 
NatL2 in nataxazole biosynthesis: NatL2 was proposed 
to participate in the incorporation of the second 3HAA 
unit, while NatL1 might work on the condensation of 
6MSA with 3HAA [7]. The small yields of 6 in ΔcbxA/
pnatPK and ΔcbxA/pnatL2-PK might be due by the 
activity of CbxC.
Finally, mutasynthesis experiments revealed some 
unexpected results. Curiously, the addition of 2,5-dihy-
droxybenzoate leads to the production of 1 and 2, 
through an unknown dehydroxylating mechanism that 
presumably acts after condensation of 2,5-dihydroxy-
benzoate to 3HAA, provided that no accumulation of 
SA occurs. Likewise, 3-methoxysalicylate gets spontane-
ously demethylated to DHB to become 3, although in this 
instance, demethylation happens directly over the pre-
cursor, and DHB is indeed accumulated.
Conclusions
The diversity of benzoxazoles generated by mutasyn-
thesis, together with those obtained by heterologous 
expression of caboxamycin biosynthesis genes cbxAB-
CDE in S. albus strains, and combinatorial biosynthesis 
experiments, show that the production of a wide variety 
of benzoxazoles could be potentially achieved by the sole 
expression of cbxBCDE genes (or orthologs thereof ), sup-
plying an external source of salicylate-like compounds, or 
with the concomitant expression of other genes capable 
of synthesizing salicylates, such as cbxA or natPK. The 
biological activity of the novel compounds generated, in 
comparison with that of the parental compound, can be 
altered and occasionally improved as shown in this work.
Methods
Strains, culture conditions and plasmids
Streptomyces sp. NTK937 [2], producer of caboxamycin, 
source of caboxamycin cluster genes cbxABCDE; Strep-
tomyces sp. NTK937 gene-deleted mutant strains ΔcbxA 
and ΔcbxA/ΔentC [13] were used respectively for heter-
ologous expression of nataxazole cluster genes and for 
mutasynthesis; Streptomyces sp. Tü6176 [4], producer of 
nataxazole, source of natPK, natL1 and natL2 genes; S. 
albus J1074 [14] and S. albus B29 [15] were used as het-
erologous hosts for the expression of caboxamycin bio-
synthesis genes; E. coli DH10B (Invitrogen) and E. coli 
ET12567 (pUB307) [28] were used for subcloning and 
intergeneric conjugation, respectively.
Escherichia coli culture media LB and 2xTY were used 
as previously described [29]. Tryptone Soy Broth (TSB) 
was used for culture of Streptomyces spp., MA for conju-
gation and sporulation, and R5A for secondary metabo-
lite production [30]. Mutasynthesis assays were carried 
out by adding a final concentration of 1  mM of each 
salicylate-like compound (from a 1 M stock, dissolved in 
DMSO) at the same time of inoculation with the bacterial 
pre-culture (Additional file 1: Figure S1).
Two plasmids were used: pSETeTc [7] for integrative 
expression of the cbxABCDE genes in S. albus strains, 
and pEM4T [31] for the expression of nataxazole clus-
ter genes in ΔcbxA strain. pCR-Blunt (Invitrogen) was 
used for routine PCR product cloning for verification 
purposes.
Culture media were supplemented with their due anti-
biotic when plasmid-bearing strains were used: ampicil-
lin (100 µg/mL), apramycin (100 µg/mL for E. coli, 25 µg/
mL for Streptomyces), thiostrepton (50 µg/mL), kanamy-
cin (25  µg/mL), tetracycline (10  µg/mL), chlorampheni-
col (25 µg/mL), and/or nalidixic acid (50 µg/mL).
DNA manipulation
DNA manipulations were performed according to stand-
ard procedures for E. coli [29] and Streptomyces [28]. PCR 
amplifications were carried out with Herculase II Fusion 
DNA Polymerase (Agilent Technologies) following an 
optimized standard PCR procedure on a SureCycler 8800 
thermocycler (Agilent Technologies): initial denatura-
tion at 99.9 °C for 2 min, 30 cycles comprised of 99.9 °C 
denaturation for 10 s, 65 °C annealing for 20 s, and 72 °C 
elongation at 30  s per kb of DNA to be amplified, plus 
an extra final cycle of 72  °C for 3  min. Products of the 
expected size were cloned into pCR-Blunt for sequence 
verification. PCR products were subsequently cloned into 
appropriate vectors using the selected restriction sites 
incorporated in the oligonucleotides.
Construction of plasmids
Plasmid pSET-cbxABCDE was built from a 6  kb PCR 
fragment containing caboxamycin genes cbxABCDE. 
The PCR product was generated by using BamHI-
flanked SS/fw oligonucleotide (5′-AAGGATCCGATCT 
GCGACGTGTCGCCGTC-3′) and EcoRI-flanked oligo-
nucleotide AH/rv (5′-AGAATTCGGTGTTGTCGGG 
CATGGTG-3′). This fragment was subsequently purified, 
sequence-checked, and digested with the appropriate 
restriction enzymes, to be ligated into a BamHI/EcoRI-
digested and dephosphorylated pSETeTc.
Constructions pnatPK and pnatL2-PK, both derived 
of pEM4T, for the expression of natPK or natL2, natX 
and natPK, respectively, were previously reported [9]. 
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Plasmid pnatL1-PK, for simultaneous expression of 
natPK and natL1, was generated by blunt ended ligation 
of natL1 at the BamHI site of pnatPK. The natL1 gene 
was obtained as a PCR fragment using oligonucleotides 
ASL21/fw (5′-AGAATTCGTTCGTCTTCGGTCGGGA 
ATGCG-3′) and ASL21/rv (5′-AAGGATCCGCGACCA 
TGTCCTGCTGATCGG-3′).
Analysis of metabolites by UPLC and HPLC–MS
Cultures of selected strains or mutants were extracted 
with ethyl acetate containing 1% formic acid (to enhance 
the extraction of compounds containing ionizing groups) 
and analysed by reverse phase chromatography with an 
Acquity UPLC instrument fitted with a BEH C18 col-
umn (1.7 µm, 2.1 × 100 mm, Waters), using acetonitrile 
(AcN) and aqueous 0.1% trifluoroacetic acid (TFA) as 
eluents. The program uses an isocratic hold of 10% AcN 
for 1 min, followed by a linear gradient up to 100% AcN 
over 7  min, at a flow rate of 0.5  mL/min and a column 
temperature of 35 °C.
For HPLC–MS analysis, an Alliance chromatographic 
system coupled to a ZQ4000 mass spectrometer and a 
SunFire C18 column (3.5 µm, 2.1 × 150 mm, Waters) was 
used. Solvents were the same as above and elution was 
performed with an initial isocratic hold with 10% AcN 
during 4 min followed by a linear gradient of AcN (10–
88%) over 30  min, all at 0.25  mL/min. MS analysis was 
done by positive mode electrospray ionization (ESI), with 
a capillary voltage of 3  kV and a cone voltage of 20  V. 
Spectral identification and characterization of peaks was 
performed in both cases by photodiode array detection 
at 330 nm, using Empower software (Waters) to extract 
bidimensional chromatograms at different wavelengths, 
depending on the spectral characteristics of the desired 
compound.
Isolation and structural characterization of compounds
Liquid production cultures were generally incubated 
at 30 °C and 250 rpm for 7 days and then 1 mL samples 
from each of the flasks were extracted with an equal vol-
ume of acidified ethyl acetate. Solid production cultures 
were carried out using 25-well plates with 1.5  mL solid 
R5A medium each and inoculated with a sterile cotton 
swab, then incubated at 30  °C for 7  days and extracted 
with an equal volume of acidified ethyl acetate. Both 
types of samples were subsequently vacuum-dried and 
redissolved in 50:50 DMSO:MeOH before chromato-
graphic analysis.
Products 4–6, 8–10, 14 and 16–19 were isolated from 
5  ×  400  mL (in 2  L flasks) cultures whose supernatants 
were first filtered, then concentrated on a C18 cartridge 
(10  g, Waters), and subsequently fractioned on a 0.1% 
TFA–MeOH gradient. Fractions were submitted to UPLC 
analysis, and those containing desired compounds were 
dried in vacuo, resuspended in 50:50 DMSO:MeOH, and 
processed on a preparative HPLC SunFire C18 column 
(10 µm, 10 × 250 mm, Waters) using experimentally deter-
mined isocratic mixtures of 0.05% TFA with either AcN 
or MeOH at 5  mL/min. The purity of the isolated peaks 
was determined by HPLC–MS before structural elucida-
tion. The isolated compounds were then dried in vacuo, 
resuspended in 50:50 tert-butanol:water and lyophilised. 
Yield and productivity of each compound was as follows: 
4, 14.3 mg (7.15 µg/mL); 5, 6.8 mg (4.2 µg/mL); 6, 0.2 mg 
(0.1  µg/mL); 8, 1.6  mg (0.8  µg/mL); 9, 2.1  mg (1.05  µg/
mL); 10, 0.5 mg (0.25 µg/mL); 14, 2.5 mg (1.25 µg/mL); 16, 
1.3 mg (0.65 µg/mL); 17, 0.7 mg (0.35 µg/mL); 18, 0.3 mg 
(0.15 µg/mL); and 19, 0.5 mg (0.15 µg/mL).
Structural elucidation was carried out at Fundación 
Medina (Granada, Spain) by a combination of 1H, 13C, 
COSY and HSQC experiments using DMSO-d6 as sol-
vent (Additional file  2: Figure S2, Tables S1–S11). LC-
DAD-HRMS analysis was carried out on an Agilent 1200 
Rapid Resolution HPLC system coupled to a Bruker 
maXis mass spectrometer. For the NMR analysis the 
samples were dissolved in DMSO-d6 and transferred to 
a 1.7 mm tube. Acquisitions were carried out on a Bruker 
AVANCE III 500  MHz spectrometer equipped with a 
1.7 mm TCI Microcryoprobe. All spectra (1H, 13C, COSY, 
HSQC, HMBC) were registered at 24  °C (Additional 
file 3: Figures S3–S13).
Bioactivity assays
The antibiotic activities of 4–6, 8–10, 14 and 16–19 were 
analyzed with an antibiotic disk diffusion assay against S. 
albus J1074, E. coli, S. aureus and M. luteus. The antifun-
gal activity was tested against C. albicans. In all cases 1, 
2.5, 5, 10, and 20  µg of each compound were used and 
loaded on 6 mm paper disks. Plates were incubated over-
night at 37 °C for E. coli, S. aureus and M.luteus, and at 
30 °C for S. albus J1074 and C. albicans (Additional file 4: 
Table S12).
Cytotoxic activity of compounds 4–14 was tested 
against the following human tumor cell lines: colon 
adenocarcinoma (HT29), non-small cell lung cancer 
(A549), breast adenocarcinoma (MDA-MB-231), gas-
tric carcinoma (AGS), and ovarian carcinoma (A2780). 
Mouse embryonic fibroblast cell line NIH/3T3 was used 
as control to evaluate cytotoxicity against non-malignant 
cells (Additional file 4: Table S13). Cells were previously 
grown for a week on DMEM-10%FBS medium, then ali-
quoted to 5000 cells per well in 96-well plates using the 
Cell counting kit-8-(96992) (Sigma-Aldrich) and grown 
for an extra 24 h. Compounds were dissolved in DMSO, 
keeping in mind that final concentration of DMSO in the 
assays should be kept at 0.1%. After the incubation, 10 μL 
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of compound (in diverse concentrations) were added to 
each well and incubated for another 48  h. Lastly, 10  μL 
of CCK-8 reagent (Sigma-Aldrich) were added, left to 
develop for 2 h in the incubator, and measured at 450 nm 
using an Elisa Bio-tek ELx 800 (BioTek).
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